Systolic blood pressure time in target range and long-term outcomes in patients with ischemic cardiomyopathy

被引:6
作者
Fu, Guangguo [1 ]
Zhou, Zhuoming [1 ]
Jian, Bohao [1 ]
Huang, Suiqing [1 ]
Feng, Zicong [1 ]
Liang, Mengya [1 ]
Liu, Quan [1 ]
Huang, Yang [1 ]
Liu, Kaizheng [1 ]
Chen, Guangxian [1 ,2 ]
Wu, Zhongkai [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiac Surg, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Cardiac Surg, 58 Zhongshan 2 Rd, Guangzhou 510080, Peoples R China
基金
中国国家自然科学基金;
关键词
ARTERY-BYPASS SURGERY; HEART-FAILURE; SURGICAL-TREATMENT; MORTALITY; ASSOCIATION; DISEASE; RISK;
D O I
10.1016/j.ahj.2022.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The relationship between the degree of systolic blood pressure (SBP) control and outcomes remains unclear in patients with ischemic cardiomyopathy (ICM). Current control metrics may not take into account the potential effects of SBP fluctuations over time on patients.Methods This study was a post-hoc analysis of the surgical treatment of ischemic heart failure trial which enrolled 2,136 participants with ICM. Our SBP target range was defined as 110 to 130 mm Hg and the time in target range (TTR) was calculated by linear interpolation.Results A total of 1,194 patients were included. Compared with the quartile 4 group (TTR 77.87%-100%), the adjusted hazard ratios and 95% confidence intervals of all-cause mortality were 1.32 (0.98-1.78) for quartile 3 group (TTR 54.81%-77.63%), 1.40 (1.03-1.90) for quartile 2 group (TTR 32.59%-54.67%), and 1.53 (1.14-2.04) for quartile 1 group (TTR 0%-32.56%). Per 29.28% (1-SD) decrement in TTR significantly increased the risk of all-cause mortality (1.15 [1.04-1.26]). Similar results were observed in the cardiovascular (CV) mortality and the composite outcome of all-cause mortality plus CV rehospitalization, and in the subgroup analyses of either coronary artery bypass grafting or medical therapy, and different baseline SBP.Conclusions In patients with ICM, the higher TTR was significantly associated with decreased risk of all-cause mortality, CV mortality and the composite outcome of all-cause mortality plus CV rehospitalization, regardless of whether the patient received coronary artery bypass grafting or medical therapy, and the level of baseline SBP. TTR may be a surrogate metric of long-term SBP control in patients with ICM. (Am Heart J 2023;258:177-185.)
引用
收藏
页码:177 / 185
页数:9
相关论文
共 30 条
[1]   The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial [J].
Andersson, Bert ;
She, Lilin ;
Tan, Ru-San ;
Jeemon, Panniyammakal ;
Mokrzycki, Krzysztof ;
Siepe, Matthias ;
Romanov, Alexander ;
Favaloro, Liliana E. ;
Djokovic, Ljubomir T. ;
Raju, P. Krishnam ;
Betlejewski, Piotr ;
Racine, Normand ;
Ostrzycki, Adam ;
Nawarawong, Weerachai ;
Das, Siuli ;
Rouleau, Jean L. ;
Sopko, George ;
Lee, Kerry L. ;
Velazquez, Eric J. ;
Panza, Julio A. .
EUROPEAN HEART JOURNAL, 2018, 39 (37) :3464-+
[2]   Systolic Blood Pressure and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction [J].
Arundel, Cherinne ;
Lam, Phillip H. ;
Gill, Gauravpal S. ;
Patel, Samir ;
Panjrath, Gurusher ;
Faselis, Charles ;
White, Michel ;
Morgan, Charity J. ;
Allman, Richard M. ;
Aronow, Wilbert S. ;
Singh, Steven N. ;
Fonarow, Gregg C. ;
Ahmed, Ali .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (24) :3054-3063
[3]   Association of systolic blood pressure with mortality in patients with heart failure with reduced ejection fraction: A complex relationship [J].
Ather, Sameer ;
Chan, Wenyaw ;
Chillar, Annirudha ;
Aguilar, David ;
Pritchett, Allison M. ;
Ramasubbu, Kumudha ;
Wehrens, Xander H. T. ;
Deswal, Anita ;
Bozkurt, Biykem .
AMERICAN HEART JOURNAL, 2011, 161 (03) :567-573
[4]   Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial [J].
Boehm, Michael ;
Ferreira, Joao Pedro ;
Mahfoud, Felix ;
Duarte, Kevin ;
Pitt, Bertram ;
Zannad, Faiez ;
Rossignol, Patrick .
EUROPEAN HEART JOURNAL, 2020, 41 (17) :1673-1683
[5]   The pathophysiology of heart failure with preserved ejection fraction [J].
Borlaug, Barry A. .
NATURE REVIEWS CARDIOLOGY, 2014, 11 (09) :507-515
[6]   Hypertension in 2017-What Is the Right Target? [J].
Chobanian, Aram V. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (06) :579-580
[7]   Impact of a pharmacist-physician collaborative care model on time-in-therapeutic blood pressure range in patients with hypertension [J].
Dixon, Dave L. ;
Parod, Eric D. ;
Sisson, Evan M. ;
Van Tassell, Benjamin W. ;
Nadpara, Pramit A. ;
Dow, Alan .
JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2020, 3 (02) :404-409
[8]   Time in Therapeutic Range, as a Determinant of All-Cause Mortality in Patients With Hypertension [J].
Doumas, Michael ;
Tsioufis, Costas ;
Fletcher, Ross ;
Amdur, Richard ;
Faselis, Charles ;
Papademetriou, Vasilios .
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (11)
[9]  
Farsky PS, 2021, J THORAC CARDIOV SUR
[10]   Range and Cardiovascular Outcomes in Patients With Hypertension [J].
Fatani, Nayyra ;
Dixon, Dave L. ;
Van Tassell, Benjamin W. ;
Fanikos, John ;
Buckley, Leo F. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (10) :1290-1299